Alclofenac

CHEMBL94081 Phase 4 Zugelassen Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
226.6 g/mol
LogP
2.5
Phase
4

A nonsteroidal anti-inflammatory drug (NSAID) that reduces pain and inflammation by inhibiting prostaglandin synthesis. Though largely withdrawn from many markets due to hypersensitivity concerns, it was used for arthritis and musculoskeletal pain management.

Molekularmasse

226,6500 g/mol

LogP

2,50

TPSA

46,50 Ų

Lipinski-Regel der Fünf

Bestanden

Wirkmechanismus

Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.

2D-Struktur

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

C=CCOc1ccc(CC(=O)O)cc1Cl

InChI

InChI=1S/C11H11ClO3/c1-2-5-15-10-4-3-8(6-9(10)12)7-11(13)14/h2-4,6H,1,5,7H2,(H,13,14)

Molecular Formula

C11H11ClO3

HBD / HBA

1 / 3

Rotierbare Bindungen

5

Schwere Atome

15

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

A nonsteroidal anti-inflammatory drug (NSAID) that reduces pain and inflammation by inhibiting prostaglandin synthesis. Though largely withdrawn from many markets due to hypersensitivity concerns, it was used for arthritis and musculoskeletal pain management.

Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.

Yes, Alclofenac is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL94081. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 30951. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.